Abstract
Glaucoma, a leading cause of irreversible blindness worldwide, is often not diagnosed until many years after disease onset. Early and objective diagnostic measures are yet missing. Besides the main risk factor, an elevated intraocular pressure (IOP), age, sex, and ethnicity are known to affect disease progression and severity. Furthermore, oxidative stress, elevated glutamate concentrations, and an autoimmune component are considered possible risk factors. We could identify several potential proteomic biomarkers in glaucoma and examine distinct changes in the glaucomatous human retina proteome. Using an experimental autoimmune glaucoma animal (EAG) model we could demonstrate an IOP-independent loss of retinal ganglion cells (RGC), which is accompanied by antibody depositions and increased levels of microglia. In a different animal model we showed that intermittent IOP elevations provoke neurodegeneration in the optic nerve and the retina and elicit changes of IgG autoantibody reactivities. The correlation between neuronal damage and changes in autoantibody reactivity suggests that autoantibody profiling could be a useful biomarker for glaucoma. In vivo studies on neuroretinal cells and porcine retinal explants demonstrated a protective effect of antibodies (eg, anti-GFAP) on RGC, which seems to be the result of reduced stress levels in the retina. We conclude that the absence of some autoantibodies in glaucoma patients reflects a loss of the protective potential of natural autoimmunity and may thus encourage neurodegenerative processes. Concluding, autoantibody profiles resemble useful biomarkers for diagnosis, progression and severity of glaucoma. Future longitudinal studies will help to improve early detection and enable better monitoring of disease progression.
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Tuulonen A, Airaksinen PJ, Erola E, Forsman E, Friberg K, Kaila M et al. The Finnish evidence-based guideline for open-angle glaucoma. Acta Ophthalmol Scand 2003; 81 (1): 3–18.
Quigley HA . Number of people with glaucoma worldwide. Br J Ophthalmol 1996; 80 (5): 389–393.
Leske MC, Connell AM, Schachat AP, Hyman L . The Barbados Eye Study. Prevalence of open angle glaucoma. Arch Ophthalmol 1994; 112 (6): 821–829.
Rudnicka AR, Mt-Isa S, Owen CG, Cook DG, Ashby D . Variations in primary open-angle glaucoma prevalence by age, gender, and race: a Bayesian meta-analysis. Invest Ophthalmol Vis Sci 2006; 47 (10): 4254–4261.
Friedman DS, Wilson MR, Liebmann JM, Fechtner RD, Weinreb RN . An evidence-based assessment of risk factors for the progression of ocular hypertension and glaucoma. Am J Ophthalmol 2004; 138 (3 Suppl): S19–S31.
Wilson MR . The myth of '21'. J Glaucoma 1997; 6 (2): 75–77.
Quigley HA, Broman AT . The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol 2006; 90 (3): 262–267.
Tezel G, Yang X, Luo C, Kain AD, Powell DW, Kuehn MH et al. Oxidative stress and the regulation of complement activation in human glaucoma. Invest Ophthalmol Vis Sci 2010; 51 (10): 5071–5082.
Yanagi M, Kawasaki R, Wang JJ, Wong TY, Crowston J, Kiuchi Y . Vascular risk factors in glaucoma: a review. Clin Experiment Ophthalmol 2011; 39 (3): 252–258.
Dreyer EB, Zurakowski D, Schumer RA, Podos SM, Lipton SA . Elevated glutamate levels in the vitreous body of humans and monkeys with glaucoma. Arch Ophthalmol 1996; 114 (3): 299–305.
Neufeld AH . Nitric oxide: a potential mediator of retinal ganglion cell damage in glaucoma. Surv Ophthalmol 1999; 43 (Suppl 1): S129–S135.
Bell K, Gramlich OW, Von Thun Und Hohenstein-Blaul N, Beck S, Funke S, Wilding C et al. Does autoimmunity play a part in the pathogenesis of glaucoma? Prog Retin Eye Res 2013; 36: 199–216.
Wax MB . The case for autoimmunity in glaucoma. Exp Eye Res 2011; 93 (2): 187–190.
Bhattacharya SK, Lee RK, Grus FH . Molecular biomarkers in glaucoma. Invest Ophthalmol Vis Sci 2013; 54 (1): 121–131.
Leske MC, Heijl A, Hussein M, Bengtsson B, Hyman L, Komaroff E . Factors for glaucoma progression and the effect of treatment: the early manifest glaucoma trial. Arch Ophthalmol 2003; 121 (1): 48–56.
Heijl A, Leske MC, Bengtsson B, Hyman L, Hussein M . Reduction of intraocular pressure and glaucoma progression: results from the Early Manifest Glaucoma Trial. Arch Ophthalmol 2002; 120 (10): 1268–1279.
Burr JM, Mowatt G, Hernandez R, Siddiqui MA, Cook J, Lourenco T et al. The clinical effectiveness and cost-effectiveness of screening for open angle glaucoma: a systematic review and economic evaluation. Health Technol Assess 2007; 11 (41)iii-iv, ix-x 1–190.
Quigley HA, Katz J, Derick RJ, Gilbert D, Sommer A . An evaluation of optic disc and nerve fiber layer examinations in monitoring progression of early glaucoma damage. Ophthalmology 1992; 99 (1): 19–28.
Quigley HA, Dunkelberger GR, Green WR . Retinal ganglion cell atrophy correlated with automated perimetry in human eyes with glaucoma. Am J Ophthalmol 1989; 107 (5): 453–464.
Burr JM, Campbell MK, Campbell SE, Francis JJ, Greene A, Hernandez R et al. Developing the clinical components of a complex intervention for a glaucoma screening trial: a mixed methods study. BMC Med Res Methodol 2011; 11: 54.
Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001; 69 (3): 89–95.
Thanos S, Bohm MR, Meyer zu Horste M, Prokosch-Willing V, Hennig M, Bauer D et al. Role of crystallins in ocular neuroprotection and axonal regeneration. Prog Retin Eye Res 2014; 42: 145–161.
Lutjen-Drecoll E, May CA, Polansky JR, Johnson DH, Bloemendal H, Nguyen TD . Localization of the stress proteins alpha B-crystallin and trabecular meshwork inducible glucocorticoid response protein in normal and glaucomatous trabecular meshwork. Invest Ophthalmol Vis Sci 1998; 39 (3): 517–525.
Sacca SC, Centofanti M, Izzotti A . New proteins as vascular biomarkers in primary open angle glaucomatous aqueous humor. Invest Ophthalmol Vis Sci 2012; 53 (7): 4242–4253.
Grus FH, Joachim SC, Sandmann S, Thiel U, Bruns K, Lackner KJ et al. Transthyretin and complex protein pattern in aqueous humor of patients with primary open-angle glaucoma. Mol Vis 2008; 14: 1437–1445.
Funke S, Perumal N, Beck S, Gabel-Scheurich S, Schmelter C, Teister J et al. Glaucoma related Proteomic Alterations in Human Retina Samples. Sci Rep 2016; 6: 29759.
Joachim SC, Grus FH, Pfeiffer N . Analysis of autoantibody repertoires in sera of patients with glaucoma. Eur J Ophthalmol 2003; 13 (9-10): 752–758.
Grus FH, Joachim SC, Hoffmann EM, Pfeiffer N . Complex autoantibody repertoires in patients with glaucoma. Mol Vis 2004; 10: 132–137.
Joachim SC, Reichelt J, Berneiser S, Pfeiffer N, Grus FH . Sera of glaucoma patients show autoantibodies against myelin basic protein and complex autoantibody profiles against human optic nerve antigens. Graefes Arch Clin Exp Ophthalmol 2008; 246 (4): 573–580.
Joachim SC, Pfeiffer N, Grus FH . Autoantibodies in patients with glaucoma: a comparison of IgG serum antibodies against retinal, optic nerve, and optic nerve head antigens. Graefes Arch Clin Exp Ophthalmol 2005; 243 (8): 817–823.
Joachim SC, Wuenschig D, Pfeiffer N, Grus FH . IgG antibody patterns in aqueous humor of patients with primary open angle glaucoma and pseudoexfoliation glaucoma. Mol Vis 2007; 13: 1573–1579.
Grus FH, Joachim SC, Bruns K, Lackner KJ, Pfeiffer N, Wax MB . Serum autoantibodies to alpha-fodrin are present in glaucoma patients from Germany and the United States. Invest Ophthalmol Vis Sci 2006; 47 (3): 968–976.
Joachim SC, Bruns K, Lackner K, Pfeiffer N, Grus FH . Antibodies to alphaB-Crystallin, Vimentin, and Heat Shock Protein 70 in Aqueous Humor of patients with Normal Tension Glaucoma and IgG Antibody Patterns Against Retinal Antigen in Aqueous Humor. Curr Eye Res 2007; 32: 501–509.
Joachim SC, Wax MB, Seidel P, Pfeiffer N, Grus FH . Enhanced characterization of serum autoantibody reactivity following HSP 60 immunization in a rat model of experimental autoimmune glaucoma. Curr Eye Res 2010; 35 (10): 900–908.
Joachim SC, Grus FH, Kraft D, White-Farrar K, Barnes G, Barbeck M et al. Complex antibody profile changes in an experimental autoimmune glaucoma animal model. Invest Ophthalmol Vis Sci 2009; 50 (10): 4734–4742.
Gramlich OW, Joachim SC, Gottschling PF, Laspas P, Cuny CS, Pfeiffer N et al. Ophthalmopathology in rats with MBP-induced experimental autoimmune encephalomyelitis. Graefes Arch Clin Exp Ophthalmol 2011; 249 (7): 1009–1020.
Laspas P, Gramlich OW, Muller HD, Cuny CS, Gottschling PF, Pfeiffer N et al. Autoreactive antibodies and loss of retinal ganglion cells in rats induced by immunization with ocular antigens. Invest Ophthalmol Vis Sci 2011; 52 (12): 8835–8848.
Joachim SC, Gramlich OW, Laspas P, Schmid H, Beck S, von Pein HD et al. Retinal ganglion cell loss is accompanied by antibody depositions and increased levels of microglia after immunization with retinal antigens. PLoS One 2012; 7 (7): e40616.
Joachim SC, Mondon C, Gramlich OW, Grus FH, Dick HB . Apoptotic retinal ganglion cell death in an autoimmune glaucoma model is accompanied by antibody depositions. J Mol Neurosci 2014; 52 (2): 216–224.
Noristani R, Kuehn S, Stute G, Reinehr S, Stellbogen M, Dick HB et al. Retinal and Optic Nerve Damage is Associated with Early Glial Responses in an Experimental Autoimmune Glaucoma Model. J Mol Neurosci 2016; 58 (4): 470–482.
Gramlich OW, Lueckner TC, Kriechbaum M, Teister J, Tao X, von Pein HD et al. Dynamics, alterations, and consequences of minimally invasive intraocular pressure elevation in rats. Invest Ophthalmol Vis Sci 2014; 55 (1): 600–611.
Joos KM, Li C, Sappington RM . Morphometric changes in the rat optic nerve following short-term intermittent elevations in intraocular pressure. Invest Ophthalmol Vis Sci 2010; 51 (12): 6431–6440.
Gramlich OW, Teister J, Neumann M, Tao X, Beck S, von Pein HD et al. Immune response after intermittent minimally invasive intraocular pressure elevations in an experimental animal model of glaucoma. J Neuroinflammation 2016; 13 (1): 82.
Bell K, Wilding C, Funke S, Pfeiffer N, Grus FH . Protective effect of 14-3-3 antibodies on stressed neuroretinal cells via the mitochondrial apoptosis pathway. BMC Ophthalmol 2015; 15 (1): 64.
Wilding C, Bell K, Beck S, Funke S, Pfeiffer N, Grus FH . Gamma-synuclein antibodies have neuroprotective potential on neuroretinal cells via proteins of the mitochondrial apoptosis pathway. PLoS One 2014; 9 (3): e90737.
Wilding C, Bell K, Funke S, Beck S, Pfeiffer N, Grus FH . GFAP antibodies show protective effect on oxidatively stressed neuroretinal cells via interaction with ERP57. J Pharmacol Sci 2015; 127 (3): 298–304.
Bell K, Wilding C, Funke S, Perumal N, Beck S, Wolters D et al. Neuroprotective effects of antibodies on retinal ganglion cells in an adolescent retina organ culture. J Neurochem 2016; 139 (2): 256–269.
Bringmann A, Pannicke T, Grosche J, Francke M, Wiedemann P, Skatchkov SN et al. Muller cells in the healthy and diseased retina. Prog Retin Eye Res 2006; 25 (4): 397–424.
Gramlich OW, Beck S, von Thun Und Hohenstein-Blaul N, Boehm N, Ziegler A, Vetter JM et al. Enhanced insight into the autoimmune component of glaucoma: IgG autoantibody accumulation and pro-inflammatory conditions in human glaucomatous retina. PLoS One 2013; 8 (2): e57557.
Boehm N, Wolters D, Thiel U, Lossbrand U, Wiegel N, Pfeiffer N et al. New insights into autoantibody profiles from immune privileged sites in the eye: a glaucoma study. Brain Behav Immun 2012; 26 (1): 96–102.
Acknowledgements
We are grateful to our collaborators that have contributed to the various studies in the Laboratory of Experimental and Translational Ophthalmology over the years. This research was supported in part by research grants from DFG (Deutsche Forschungsgemeinschaft, research funding organization in Germany); MAIFOR university Mainz, Forschungsschwerpunkt Translationale Neurowissenschaften (FTN, university Mainz), Stiftung Rheinland- Pfalz für Innovation (research funding organization in Germany) and Deutsche Ophthalmologische Gesellschaft (German Ophthalmic Society).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Von Thun Und Hohenstein-Blaul, N., Kunst, S., Pfeiffer, N. et al. Biomarkers for glaucoma: from the lab to the clinic. Eye 31, 225–231 (2017). https://doi.org/10.1038/eye.2016.300
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2016.300
This article is cited by
-
Emerging trends in long-acting sustained drug delivery for glaucoma management
Drug Delivery and Translational Research (2025)
-
Uveitic glaucoma-like features in Yap conditional knockout mice
Cell Death Discovery (2024)
-
Sensitivity and specificity of the uniform field electroretinogram in glaucoma detection in comparison to the pattern electroretinogram
Documenta Ophthalmologica (2024)
-
Role of T cell-induced autoimmune response in the pathogenesis of glaucoma
International Ophthalmology (2024)
